M

MGX

MGX

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
5%Bearish
Buy/Sell Ratio20% buys
BearishBullish
MGX Live QuoteReal-time
$0.61
$0.22(-26.05%)1M
Day Range$0.61 – $0.64
Open$0.63
Previous Close$0.63
Volume124.5K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$23.89M
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-2.50
Price to Book0.3
Dividend Yield0.65%
Beta (Volatility)0.83
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $0.61 (1%)
Low: $0.60High: $1.87
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$7.00-95.3% upside

Insider Buys

1

$23K

Insider Sales

25

$94K

Total Volume

$118K

35 transactions

Net Activity

$71K

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
25CONFIDENCE

Sentiment Rating

Moderate Distribution

CEO Conviction Index

Liquidating / Profit Taking

Key Drivers

  • •Heavy distribution: sales represent 80% of total transaction value.
  • •CEO selling activity detected. Often driven by option expiration or diversification plans.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
M
1

Multiple Insiders

P - Purchase Insiders

0 buys9 sells

$400.00M total

T
2

Thomas Brian C.

Dir

0 buys3 sells

$31K total

I
3

Irish Jian

See Remarks

0 buys6 sells

$27K total

R
4

Reid Laurence

Dir

1 buys0 sells

$23K total

W
5

Wapnick Pamela

CFO

0 buys8 sells

$23K total

Trading History
MGX insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Sep 9, 2026

2 months ago

Reid Laurence

Dir

Director
Buy20.0K$1.17$23K

Sep 9, 2026

2 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell20.0K$20000.00$400.00M

Sep 8, 2026

2 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell126.1K$-358.00$0

Sep 8, 2026

2 months ago

Wein Matthew

See Remarks

Insider
Sell358$1.16$415

Sep 8, 2026

2 months ago

Irish Jian

See Remarks

Insider
Sell2.1K$1.16$2K

Sep 8, 2026

2 months ago

Wapnick Pamela

CFO

CFO
Sell1.9K$1.16$2K

Jun 5, 2026

5 months ago

Irish Jian

See Remarks

Insider
Sell3.7K$1.30$5K

Jun 5, 2026

5 months ago

Wapnick Pamela

CFO

CFO
Sell2.9K$1.30$4K

Jun 5, 2026

5 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell208.5K$-2884.00$0

Jun 5, 2026

5 months ago

Wein Matthew

See Remarks

Insider
Sell558$1.30$725

Mar 5, 2026

8 months ago

Wein Matthew

See Remarks

Insider
Sell482$1.60$771

Mar 5, 2026

8 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell187.4K$-1581.00$0

Mar 5, 2026

8 months ago

Wapnick Pamela

CFO

CFO
Sell1.6K$1.60$3K

Mar 5, 2026

8 months ago

Irish Jian

CEO

CEO
Sell1.6K$1.60$3K

Dec 5, 2025

11 months ago

Thomas Brian C.

Dir

Director
Sell3.8K$1.77$7K

Dec 5, 2025

11 months ago

Wein Matthew

See Remarks

Insider
Sell199$1.77$353

Dec 5, 2025

11 months ago

Wapnick Pamela

CFO

CFO
Sell1.6K$1.77$3K

Dec 5, 2025

11 months ago

Irish Jian

CEO

CEO
Sell1.6K$1.77$3K

Dec 5, 2025

11 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell2.51M$-3830.00$0

Sep 5, 2025

14 months ago

Thomas Brian C.

Dir

Director
Sell2.7K$1.81$5K

Sep 5, 2025

14 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell2.51M$-2701.00$0

Sep 5, 2025

14 months ago

Wein Matthew

See Remarks

Insider
Sell199$1.81$360

Sep 5, 2025

14 months ago

Irish Jian

CEO

CEO
Sell1.6K$1.81$3K

Sep 5, 2025

14 months ago

Wapnick Pamela

CFO

CFO
Sell1.6K$1.81$3K

Jun 6, 2025

17 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell16.7K$-199.00$0

Jun 6, 2025

17 months ago

Wein Matthew

See Remarks

Insider
Sell199$1.75$348

Jun 6, 2025

17 months ago

Noonberg Sarah B.

Chief Medical Officer

C-Level
Sell5.2K$1.75$9K

Jun 6, 2025

17 months ago

Wapnick Pamela

CFO

CFO
Sell1.6K$1.75$3K

Jun 6, 2025

17 months ago

Thomas Brian C.

CEO

CEO
Sell10.8K$1.75$19K

Jun 6, 2025

17 months ago

Irish Jian

See Remarks

Insider
Sell6.4K$1.75$11K

Mar 5, 2025

20 months ago

Wapnick Pamela

CFO

CFO
Sell1.8K$1.87$3K

Mar 5, 2025

20 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell9.5K$-930.00$0

Mar 5, 2025

20 months ago

Wein Matthew

See Remarks

Insider
Sell930$1.87$2K

Dec 5, 2024

23 months ago

Wapnick Pamela

CFO

CFO
Sell1.6K$1.86$3K

Dec 5, 2024

23 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell61.5K$-1559.00$0
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
MGX Buy Conviction20%
Industry Rank#0 of 570
Volume Contribution0.0%
Total Industry Activity$16.44B

MGX has an insider buy conviction of 20%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for MGX

Over the last 90 days, corporate insiders at MGX (MGX) engaged in a total of 35 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 25 were sales. The total volume of insider trading reached $118K.

The net insider activity for MGX shows a net selling bias of $71K. This activity represents a 20% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 20.0K shares valued at $400.00M on Sep 9, 2026.

Live Market News & Developments
Aggregated real-time headlines for MGX (MGX)
6 updates

MGX Forecast — Price Target — Prediction for 2027

TradingView147d ago

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates

Yahoo Finance189d ago

Metagenomi Therapeutics (NasdaqGS:MGX) Stock Forecast & Analyst Predictions

Simply Wall St9d ago

A potential one-time hemophilia A treatment is planned for a global trial in 2027, pending regulatory clearance.

Stock Titan15d ago

symbol__ Stock Quote Price and Forecast

CNN1015d ago

Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?

Yahoo Finance280d ago

FAQs About MGX Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for MGX.

Based on SEC Form 4 disclosures, the Insider Confidence Score for MGX is currently 25/100, which reflects a moderate distribution bias. This calculation accounts for a total of 1 purchases and 25 sales by company executives over the last 90 days.

The CEO Conviction Index for MGX is rated as "Liquidating / Profit Taking". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.